Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment

Lancet Rheumatol. 2020 Nov;2(11):e653-e655. doi: 10.1016/S2665-9913(20)30309-X. Epub 2020 Sep 5.
No abstract available